IDIDFC MFDirect · IDCW

Bandhan Healthcare Fund - IDCW Reinvest - Direct Plan

Pharma & Health CareEquity - Sectoral Fund - Pharma & Health CareBenchmark: BSE Health Care - TRI
NAV · 16 Sep 2026₹11.24-0.28%
AUM₹332 Crfrom this fund's primary plan
Expense Ratio1.22%
CAGR
Exit Load0.50% on or before 30D, Nil after 30D
Min SIP₹100from this fund's primary plan
Launched2025

Investment Objective

The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.

Fund Mandate

Debt Securities and Money Market Instruments (including G-Sec, Securitised debt)0%–20%
Equity & Equity related securities other than above and overseas securities0%–20%
Equity & equity related instruments engaged in Healthcare, Pharma and Allied sectors80%–100%
Units issued by REITs & InvITs0%–10%
Asset Allocation
Domestic Equity96.0%
Cash & Equivalents4.0%
Fund Managers
VK
Viraj Kulkarni
Fund Manager
Key Information
1.22%
₹100from this fund's primary plan
₹1,000
0.50% on or before 30D, Nil after 30D
Nil
Inception28 Nov 2025
AMCIDFC MF
Top Holdings
1Sun Pharmaceutical Industries Ltd.Healthcare10.48%
2Cipla Ltd.Healthcare6.38%
3Max Healthcare Institute Ltd.Healthcare5.81%
4Apollo Hospitals Enterprise Ltd.Healthcare5.64%
5Triparty Repo TRP_010926Miscellaneous4.33%
6Divi's Laboratories Ltd.Healthcare4.28%
7Aurobindo Pharma Ltd.Healthcare4.14%
8Lupin Ltd.Healthcare3.96%
9Shilpa Medicare Ltd.Healthcare3.72%
10Glaxosmithkline Pharmaceuticals Ltd.Healthcare3.68%
Sector Allocation
Healthcare91.2%
Miscellaneous4.3%
Business Services3.3%
Trading1.5%
Trailing Returns
PeriodReturnsCategory avg
1 Day-0.28%
1 Week-2.33%-2.04%
1 Month-1.15%-3.83%
3 Months+8.37%+0.39%
6 Months+18.97%+9.03%
9 Months+14.78%+2.70%
+12.37%+16.24%

Category avg is the average return of every scheme in this fund's SEBI class (Equity - Sectoral Fund - Pharma & Health Care) over the same period. Returns up to 1 year are absolute; returns beyond 1 year are annualised (CAGR). This is Accord's own stated convention for equity-oriented schemes.

Risk Metrics

Risk metrics are not available for this fund.

Fees
1.22%
0.50% on or before 30D, Nil after 30D
Nil
₹100from this fund's primary plan
₹1,000
Capital Gains Tax, general rules

This is an equity-oriented fund. Under rules effective since Budget 2024 (23 July 2024):

Short-Term Capital Gains (held ≤ 12 months): taxed at a flat 20%.

Long-Term Capital Gains (held > 12 months): taxed at 12.5% on gains above ₹1.25 lakh in a financial year, with no indexation benefit.

General information only, not tax advice, actual liability depends on your overall income and applicable law at the time of redemption. Consult a tax advisor for your specific situation.

Frequently Asked QuestionsGeneral mutual-fund FAQs, not specific to this scheme